Julie Brahmer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Robert Gray, R. Gray, J. Schiller, 2006, The New England journal of medicine.

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, Thomas J Smith, Gregory J Riely, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

Jing Li, Manuel Hidalgo, Alex Sparreboom, 2007, Cancer biology & therapy.

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.

Manuel Hidalgo, Ming Zhao, Mats O Karlsson, 2006, Journal of the National Cancer Institute.